following an abbreviated submission:
indacaterol/glycopyrronium/mometasone furoate (Enerzair Breezhaler®) is accepted for use within NHSScotland.
Indication under review: as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
Indacaterol/glycopyrronium/mometasone furoate (Enerzair Breezhaler®) offers an additional treatment choice of high dose inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) in a single inhaler. SMC has previously accepted an alternative LAMA as an add-on treatment to ICS and LABA in asthma.
Download detailed advice732KB (PDF)
Medicine details
- Medicine name:
- indacaterol/glycopyrronium/mometasone furoate (Enerzair Breezhaler)
- SMC ID:
- SMC2355
- Indication:
As a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 May 2021